Antibiotics Resistance Prevalence of Helicobacter pylori Strains in Northwest China

References

• Kato M, Toda A, Yamamoto-Honda R, Arase Y, Sone H. Association between Helicobacter pylori infection, eradication and diabetes mellitus. J Diabetes Investig. 2019;10(5):1341–1346. doi:10.1111/jdi.13011
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-The Maastricht V/florence consensus report. Gut. 2017;66(1):6–30. doi:10.1136/gutjnl-2016-312288
   PubMed Web of Science ®Google Scholar
• Liu WZ, Xie Y, Lu H, et al. Fifth Chinese National Consensus Report on the management ofHelicobacter pyloriinfection. Helicobacter. 2018;23(2):e12475. doi:10.1111/hel.12475
   PubMed Web of Science ®Google Scholar
• Zhong Z, Zhang Z, Wang J, et al. A retrospective study of the antibiotic-resistant phenotypes and genotypes of Helicobacter pylori strains in China. Am J Cancer Res. 2021;11(10):5027–5037.
   PubMed Web of Science ®Google Scholar
• Megraud F, Bruyndonckx R, Coenen S, et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021;70(10):1815–1822. doi:10.1136/gutjnl-2021-324032
   PubMed Web of Science ®Google Scholar
• Gökçekuyu BM, Yılmaz Ö, Soytürk M, Ellidokuz H, Akpınar H, Şimşek İ. Unacceptable antibiotic resistance rates for Helicobacter pylori in Turkey: something must change. Turk J Gastroenterol. 2021;32(3):269–275. doi:10.5152/tjg.2021.20210
   PubMed Web of Science ®Google Scholar
• Bujanda L, Nyssen OP, Vaira D, et al. Antibiotic resistance prevalence and trends in patients infected with Helicobacter pylori in the period 2013–2020: results of the European Registry on H. pylori management (HP-EuReg). Antibiotics. 2021;10(9):1058. doi:10.3390/antibiotics10091058
   Web of Science ®Google Scholar
• Zagari RM, Frazzoni L, Marasco G, Fuccio L, Bazzoli F. Treatment of Helicobacter pylori infection: a clinical practice update. Minerva Med. 2021;112(2):281–287. doi:10.23736/S0026-4806.20.06810-X
   PubMed Web of Science ®Google Scholar
• Hsieh MT, Chang WL, Wu CT, et al. Optimizing the MIC breakpoints of amoxicillin and tetracycline for antibiotic selection in the rescue therapy of H. pylori with bismuth quadruple regimen. Eur J Clin Pharmacol. 2020;76(11):1581–1589. doi:10.1007/s00228-020-02938-5
   PubMed Web of Science ®Google Scholar
• Alarcon T, Urruzuno P, Martinez MJ, et al. Antimicrobial susceptibility of 6 antimicrobial agents in Helicobacter pylori clinical isolates by using EUCAST breakpoints compared with previously used breakpoints. Enferm Infecc Microbiol Clin. 2017;35(5):278–282. doi:10.1016/j.eimc.2016.02.010
   PubMed Web of Science ®Google Scholar
• Jung DH, Kim JH, Jeong SJ, et al. Peptide nucleic acid probe-based analysis as a new detection method for clarithromycin resistance in Helicobacter pylori. Gut Liver. 2018;12(6):641–647. doi:10.5009/gnl18111
   PubMed Web of Science ®Google Scholar
• Xie C, Lu N. Review: clinical management of Helicobacter pylori infection in China. Helicobacter. 2015;20(1):1–10. doi:10.1111/hel.12178
   PubMed Web of Science ®Google Scholar
• Tian L, Yao Y, Yin L, et al. Direct detection of antibiotic resistance in Chinese Helicobacter pylori clinical isolates by sequencing-based approach. J Healthc Eng. 2022;6436256. doi:10.1155/2022/6436256
   PubMed Web of Science ®Google Scholar
• Lee Y, Chiang T, Chou C, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150(5):1113–1124.e1115. doi:10.1053/j.gastro.2016.01.028
   PubMed Web of Science ®Google Scholar
• Ma J, Yu M, Shao QQ, et al. Both family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are cost-effective for gastric cancer prevention. Helicobacter. 2022;27(4):e12911. doi:10.1111/hel.12911
   PubMed Web of Science ®Google Scholar
• Yang L, Zou A, Wu H, et al. World Health Organization: list of bacteria for which new antibiotics are urgently needed. Biomed Res Int. 2017;2021:6150628.
   Google Scholar
• Yang Q, Shang Q, Wei GQ, et al. Jinghuaweikang capsules combined with Quadruple therapy in the treatment of Helicobacter pylori infection: a multicenter, randomized, controlled, clinical study. Zhonghua Yi Xue Za Zhi. 2019;99(4):295–300. doi:10.3760/cma.j.issn.0376-2491.2019.04.012
   PubMedGoogle Scholar
• Nie SS, Song ZQ, Suo BJ, Xue Y, Meng LM, Zhou LY. The exposure of antibiotics on the eradication of bismuth quadruple therapy in H. pylori infection. Zhonghua Nei Ke Za Zhi. 2021;60(11):977–981. doi:10.3760/cma.j.cn112138-20210101-00001
   PubMedGoogle Scholar
• Kasahun GG, Demoz GT, Desta DM. Primary resistance pattern of Helicobacter pylori to antibiotics in adult population: a systematic review. Infect Drug Resist. 2020;13:1567–1573. doi:10.2147/IDR.S250200
   PubMed Web of Science ®Google Scholar
• Miftahussurur M, Waskito LA, Syam AF, et al. Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance. Infect Drug Resist. 2019;12:345–358. doi:10.2147/IDR.S187063
   PubMed Web of Science ®Google Scholar
• Song Z, Fu W, Zhou L. Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin. BMC Gastroenterol. 2019;19(1):132. doi:10.1186/s12876-019-1056-3
   PubMed Web of Science ®Google Scholar
• Dutta AK, Phull PS. Treatment of Helicobacter pylori infection in the presence of penicillin allergy. World J Gastroenterol. 2021;27(44):7661–7668. doi:10.3748/wjg.v27.i44.7661
   PubMed Web of Science ®Google Scholar
• Luo L, Huang Y, Liang X, Ji Y, Yu L, Lu H. Susceptibility-guided therapy for Helicobacter pylori-infected penicillin-allergic patients: a prospective clinical trial of first-line and rescue therapies. Helicobacter. 2020;25(4):e12699. doi:10.1111/hel.12699
   PubMed Web of Science ®Google Scholar